Gain Therapeutics Q2 net loss $7.7M; Phase 1 trial submission for GT-02287

Gain Therapeutics, Inc.

2023-Q2 EPS reported -$1.05 revenue$55,180

Net loss $7.7M ($0.62/share) vs $5.1M ($0.43) in Q2 2022, driven by higher R&D and G&A costs.
R&D expenses $4.0M, up $1.4M YoY due to preclinical studies and manufacturing for GBA1 Parkinson's program.
Cash and securities $16.2M; company expects to fund operations into Q3 2024.
Submitted HREC dossier to initiate Phase 1 trial of GT-02287 in Australia in H2 2023.
Late-breaking abstract accepted for presentation at International Congress of Parkinson's Disease.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Gain Therapeutics, Inc. reported second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023, was $7.7 million, or $0.62 per share basic and diluted, EPS $0.62 per share basic and diluted.

Period: second quarter ended June 30, 2023
Net income: Net loss for the three months ended June 30, 2023, was $7.7 million, or $0.62 per share basic and diluted
EPS: $0.62 per share basic and diluted
Result: reported results

Exact text from the filing

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced financial results for the second quarter ended June 30, 2023, and highlighted recent corporate progress.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

Gain Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-014482

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.